BRCA1 and neoplasm: In the OV_062 patient‐derived xenograft model without BRCA1 mutations but with MRE11A mutations and a high HRD score, venadaparib demonstrated a statistically significant tumor growth inhibitory effect in comparison with the control group and was superior to olaparib (100 mg/kg) [34].